LGALS3 and pulmonary fibrosis: In a phase I/IIa study, compared with healthy controls, TD139 treatment reduced Gal-3 expression in alveolar macrophages from IPF patients and reduced plasma biomarkers relevant to lung fibrosis such as PDGF-BB, PAI-1, CCL18, and CHI3L121.